<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27451467</article-id><article-id pub-id-type="pmc">5015408</article-id><article-id pub-id-type="doi">10.1161/JAHA.116.003776</article-id><article-id pub-id-type="publisher-id">JAH31637</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Preventive Cardiology</subject></subj-group></subj-group></article-categories><title-group><article-title>Electronic Alert System for Improving Stroke Prevention Among Hospitalized Oral‐Anticoagulation‐Naïve Patients With Atrial Fibrillation: A Randomized Trial</article-title><alt-title alt-title-type="left-running-head">Silbernagel et al</alt-title></title-group><contrib-group><contrib id="jah31637-cr-0001" contrib-type="author"><name><surname>Silbernagel</surname><given-names>Günther</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31637-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jah31637-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah31637-cr-0002" contrib-type="author"><name><surname>Spirk</surname><given-names>David</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31637-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jah31637-cr-0003" contrib-type="author"><name><surname>Hager</surname><given-names>Adrian</given-names></name><degrees>MA</degrees><xref ref-type="aff" rid="jah31637-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah31637-cr-0004" contrib-type="author"><name><surname>Baumgartner</surname><given-names>Iris</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31637-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah31637-cr-0005" contrib-type="author" corresp="yes"><name><surname>Kucher</surname><given-names>Nils</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31637-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="jah31637-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Division of Angiology</named-content><named-content content-type="organisation-division">Department of Internal Medicine</named-content><institution>Medical University of Graz</institution><country country="AT">Austria</country></aff><aff id="jah31637-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Department of Angiology</named-content><named-content content-type="organisation-division">Swiss Cardiovascular Center</named-content><named-content content-type="organisation-division">Inselspital</named-content><institution>University of Bern</institution><country country="CH">Switzerland</country></aff><aff id="jah31637-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Department of Medical Informatics</named-content><named-content content-type="organisation-division">Inselspital</named-content><institution>University of Bern</institution><country country="CH">Switzerland</country></aff><aff id="jah31637-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Institute of Pharmacology</named-content><institution>University of Bern</institution><country country="CH">Switzerland</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Nils Kucher, MD, Department of Vascular Medicine, Swiss Cardiovascular Center, Inselspital, University of Bern, 3010 Bern, Switzerland. E‐mail: <email>nils.kucher@insel.ch</email></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2016</year></pub-date><volume>5</volume><issue>7</issue><issue-id pub-id-type="doi">10.1002/jah3.2016.5.issue-7</issue-id><elocation-id>e003776</elocation-id><history><date date-type="received"><day>24</day><month>5</month><year>2016</year></date><date date-type="accepted"><day>15</day><month>6</month><year>2016</year></date></history><permissions><copyright-statement content-type="article-copyright">© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution‐NonCommercial‐NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-5-e003776.pdf"></self-uri><abstract id="jah31637-abs-0001"><sec id="jah31637-sec-0001"><title><offsets xml_i="5789" xml_f="5799" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="5810" xml_f="5850" txt_i="22" txt_f="62">Many patients with atrial fibrillation (</offsets><styled-content style="fixed-case"><offsets xml_i="5885" xml_f="5887" txt_i="62" txt_f="64">AF</offsets></styled-content><offsets xml_i="5904" xml_f="5942" txt_i="64" txt_f="102">) do not receive oral anticoagulants (</offsets><styled-content style="fixed-case"><offsets xml_i="5977" xml_f="5980" txt_i="102" txt_f="105">OAC</offsets></styled-content><offsets xml_i="5997" xml_f="6092" txt_i="105" txt_f="200">) for the prevention of stroke and systemic embolism. We aimed to improve the prescription of (</offsets><styled-content style="fixed-case"><offsets xml_i="6127" xml_f="6130" txt_i="200" txt_f="203">OAC</offsets></styled-content><offsets xml_i="6147" xml_f="6182" txt_i="203" txt_f="238">) among hospitalized patients with </offsets><styled-content style="fixed-case"><offsets xml_i="6217" xml_f="6219" txt_i="238" txt_f="240">AF</offsets></styled-content><offsets xml_i="6236" xml_f="6237" txt_i="240" txt_f="241">.</offsets></p></sec><sec id="jah31637-sec-0002"><title><offsets xml_i="6282" xml_f="6301" txt_i="243" txt_f="262">Methods and Results</offsets></title><p><offsets xml_i="6312" xml_f="6395" txt_i="263" txt_f="346">We developed a computer‐based electronic alert system for identifying hospitalized </offsets><styled-content style="fixed-case"><offsets xml_i="6430" xml_f="6433" txt_i="346" txt_f="349">OAC</offsets></styled-content><offsets xml_i="6450" xml_f="6471" txt_i="349" txt_f="370">‐naïve patients with </offsets><styled-content style="fixed-case"><offsets xml_i="6506" xml_f="6508" txt_i="370" txt_f="372">AF</offsets></styled-content><offsets xml_i="6525" xml_f="6556" txt_i="372" txt_f="403">. The alert system contained a </offsets><styled-content style="fixed-case"><offsets xml_i="6591" xml_f="6594" txt_i="403" txt_f="406">CHA</offsets></styled-content><offsets xml_i="6611" xml_f="6612" txt_i="406" txt_f="407">
</offsets><sub><offsets xml_i="6617" xml_f="6618" txt_i="407" txt_f="408">2</offsets></sub><offsets xml_i="6624" xml_f="6625" txt_i="408" txt_f="409">
</offsets><styled-content style="fixed-case"><offsets xml_i="6660" xml_f="6662" txt_i="409" txt_f="411">DS</offsets></styled-content><offsets xml_i="6679" xml_f="6680" txt_i="411" txt_f="412">
</offsets><sub><offsets xml_i="6685" xml_f="6686" txt_i="412" txt_f="413">2</offsets></sub><offsets xml_i="6692" xml_f="6693" txt_i="413" txt_f="414">‐</offsets><styled-content style="fixed-case"><offsets xml_i="6728" xml_f="6731" txt_i="414" txt_f="417">VAS</offsets></styled-content><offsets xml_i="6748" xml_f="6806" txt_i="417" txt_f="475">c score calculation tool and provided recommendations for </offsets><styled-content style="fixed-case"><offsets xml_i="6841" xml_f="6844" txt_i="475" txt_f="478">OAC</offsets></styled-content><offsets xml_i="6861" xml_f="6998" txt_i="478" txt_f="615"> prescription. The alert system was tested in a 1:1 randomized controlled trial at the University Hospital Bern: Patients with suspected </offsets><styled-content style="fixed-case"><offsets xml_i="7033" xml_f="7035" txt_i="615" txt_f="617">AF</offsets></styled-content><offsets xml_i="7052" xml_f="7306" txt_i="617" txt_f="871"> without an active prescription order were allocated to an alert group in which an alert was issued in the electronic patient chart and order entry system or to a control group in which no alert was issued. The primary end point was the rate of adequate </offsets><styled-content style="fixed-case"><offsets xml_i="7341" xml_f="7344" txt_i="871" txt_f="874">OAC</offsets></styled-content><offsets xml_i="7361" xml_f="7425" txt_i="874" txt_f="938"> prescription at hospital discharge, defined as prescription in </offsets><styled-content style="fixed-case"><offsets xml_i="7460" xml_f="7463" txt_i="938" txt_f="941">OAC</offsets></styled-content><offsets xml_i="7480" xml_f="7506" txt_i="941" txt_f="967">‐naïve men and women with </offsets><styled-content style="fixed-case"><offsets xml_i="7541" xml_f="7544" txt_i="967" txt_f="970">CHA</offsets></styled-content><offsets xml_i="7561" xml_f="7562" txt_i="970" txt_f="971">
</offsets><sub><offsets xml_i="7567" xml_f="7568" txt_i="971" txt_f="972">2</offsets></sub><offsets xml_i="7574" xml_f="7575" txt_i="972" txt_f="973">
</offsets><styled-content style="fixed-case"><offsets xml_i="7610" xml_f="7612" txt_i="973" txt_f="975">DS</offsets></styled-content><offsets xml_i="7629" xml_f="7630" txt_i="975" txt_f="976">
</offsets><sub><offsets xml_i="7635" xml_f="7636" txt_i="976" txt_f="977">2</offsets></sub><offsets xml_i="7642" xml_f="7643" txt_i="977" txt_f="978">‐</offsets><styled-content style="fixed-case"><offsets xml_i="7678" xml_f="7681" txt_i="978" txt_f="981">VAS</offsets></styled-content><offsets xml_i="7698" xml_f="7744" txt_i="981" txt_f="1027">c score ≥1 and ≥2, respectively. Overall, 889 </offsets><styled-content style="fixed-case"><offsets xml_i="7779" xml_f="7782" txt_i="1027" txt_f="1030">OAC</offsets></styled-content><offsets xml_i="7799" xml_f="7914" txt_i="1030" txt_f="1145">‐naïve patients (455 from the alert group and 434 from the control group) were eligible for analysis. Although the </offsets><styled-content style="fixed-case"><offsets xml_i="7949" xml_f="7952" txt_i="1145" txt_f="1148">CHA</offsets></styled-content><offsets xml_i="7969" xml_f="7970" txt_i="1148" txt_f="1149">
</offsets><sub><offsets xml_i="7975" xml_f="7976" txt_i="1149" txt_f="1150">2</offsets></sub><offsets xml_i="7982" xml_f="7983" txt_i="1150" txt_f="1151">
</offsets><styled-content style="fixed-case"><offsets xml_i="8018" xml_f="8020" txt_i="1151" txt_f="1153">DS</offsets></styled-content><offsets xml_i="8037" xml_f="8038" txt_i="1153" txt_f="1154">
</offsets><sub><offsets xml_i="8043" xml_f="8044" txt_i="1154" txt_f="1155">2</offsets></sub><offsets xml_i="8050" xml_f="8051" txt_i="1155" txt_f="1156">‐</offsets><styled-content style="fixed-case"><offsets xml_i="8086" xml_f="8089" txt_i="1156" txt_f="1159">VAS</offsets></styled-content><offsets xml_i="8106" xml_f="8281" txt_i="1159" txt_f="1334">c score module was used in only 48 (10.5%) patients from the alert group, 100 (22.0%) patients from the alert group versus 69 (15.9%) from the control group received adequate </offsets><styled-content style="fixed-case"><offsets xml_i="8316" xml_f="8319" txt_i="1334" txt_f="1337">OAC</offsets></styled-content><offsets xml_i="8336" xml_f="8371" txt_i="1337" txt_f="1372"> prescription (relative risk 1.38; </offsets><italic><offsets xml_i="8379" xml_f="8380" txt_i="1372" txt_f="1373">P</offsets></italic><offsets xml_i="8389" xml_f="8398" txt_i="1373" txt_f="1382">=0.021). </offsets><styled-content style="fixed-case"><offsets xml_i="8433" xml_f="8436" txt_i="1382" txt_f="1385">OAC</offsets></styled-content><offsets xml_i="8453" xml_f="8581" txt_i="1385" txt_f="1513"> or antiplatelet therapy was prescribed in 325 (71.4%) patients from the alert group versus 271 (62.4%) from the control group (</offsets><italic><offsets xml_i="8589" xml_f="8590" txt_i="1513" txt_f="1514">P</offsets></italic><offsets xml_i="8599" xml_f="8607" txt_i="1514" txt_f="1522">=0.004).</offsets></p></sec><sec id="jah31637-sec-0003"><title><offsets xml_i="8652" xml_f="8663" txt_i="1524" txt_f="1535">Conclusions</offsets></title><p><offsets xml_i="8674" xml_f="8731" txt_i="1536" txt_f="1593">Versus standard care, the alert system modestly improved </offsets><styled-content style="fixed-case"><offsets xml_i="8766" xml_f="8769" txt_i="1593" txt_f="1596">OAC</offsets></styled-content><offsets xml_i="8786" xml_f="8831" txt_i="1596" txt_f="1641"> prescription among consecutive hospitalized </offsets><styled-content style="fixed-case"><offsets xml_i="8866" xml_f="8868" txt_i="1641" txt_f="1643">AF</offsets></styled-content><offsets xml_i="8885" xml_f="8895" txt_i="1643" txt_f="1653"> patients.</offsets></p></sec><sec id="jah31637-sec-0004"><title><offsets xml_i="8940" xml_f="8967" txt_i="1655" txt_f="1682">Clinical Trial Registration</offsets></title><p><offsets xml_i="8978" xml_f="8979" txt_i="1683" txt_f="1684">
</offsets><styled-content style="fixed-case"><offsets xml_i="9014" xml_f="9017" txt_i="1684" txt_f="1687">URL</offsets></styled-content><offsets xml_i="9034" xml_f="9036" txt_i="1687" txt_f="1689">: </offsets><ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov"><offsets xml_i="9110" xml_f="9140" txt_i="1689" txt_f="1719">https://www.clinicaltrials.gov</offsets></ext-link><offsets xml_i="9151" xml_f="9172" txt_i="1719" txt_f="1740">. Unique identifier: </offsets><styled-content style="fixed-case"><offsets xml_i="9207" xml_f="9210" txt_i="1740" txt_f="1743">NCT</offsets></styled-content><offsets xml_i="9227" xml_f="9236" txt_i="1743" txt_f="1752">02455102.</offsets></p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah31637-kwd-0001">anticoagulants</kwd><kwd id="jah31637-kwd-0002">arrhythmia</kwd><kwd id="jah31637-kwd-0003">atrial fibrillation</kwd><kwd id="jah31637-kwd-0004">electronic alert system</kwd><kwd id="jah31637-kwd-0005">embolism</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Atrial Fibrillation</kwd><kwd>Quality and Outcomes</kwd><kwd>Anticoagulants</kwd></kwd-group><funding-group><award-group><funding-source>Bayer Healthcare AG</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Inselspital Foundation</funding-source></award-group></funding-group><counts><page-count count="11"></page-count></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jah31637</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>July 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:01.09.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jah31637-cit-1001">(<source>J Am Heart Assoc</source>. <year>2016</year>;<volume>5</volume>:e003776 doi: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.116.003776">10.1161/JAHA.116.003776</ext-link>)</mixed-citation>
</p></notes></front><body><sec id="jah31637-sec-0005"><title><offsets xml_i="10922" xml_f="10934" txt_i="1761" txt_f="1773">Introduction</offsets></title><p><offsets xml_i="10945" xml_f="11057" txt_i="1774" txt_f="1886">Atrial fibrillation (AF) is the most common heart rhythm disorder and its prevalence is consistently increasing.</offsets><xref rid="jah31637-bib-0001" ref-type="ref"><offsets xml_i="11102" xml_f="11103" txt_i="1886" txt_f="1887">1</offsets></xref><offsets xml_i="11110" xml_f="11112" txt_i="1887" txt_f="1889">, </offsets><xref rid="jah31637-bib-0002" ref-type="ref"><offsets xml_i="11157" xml_f="11158" txt_i="1889" txt_f="1890">2</offsets></xref><offsets xml_i="11165" xml_f="11260" txt_i="1890" txt_f="1985"> One quarter of all 40‐year‐olds will develop this arrhythmia during the course of their lives.</offsets><xref rid="jah31637-bib-0003" ref-type="ref"><offsets xml_i="11305" xml_f="11306" txt_i="1985" txt_f="1986">3</offsets></xref><offsets xml_i="11313" xml_f="11356" txt_i="1986" txt_f="2029"> AF increases the risk of stroke by 5 times</offsets><xref rid="jah31637-bib-0004" ref-type="ref"><offsets xml_i="11401" xml_f="11402" txt_i="2029" txt_f="2030">4</offsets></xref><offsets xml_i="11409" xml_f="11486" txt_i="2030" txt_f="2107"> and doubles the risk of cardiovascular deaths and strokes after just 1 year.</offsets><xref rid="jah31637-bib-0005" ref-type="ref"><offsets xml_i="11531" xml_f="11532" txt_i="2107" txt_f="2108">5</offsets></xref><offsets xml_i="11539" xml_f="11540" txt_i="2108" txt_f="2109">
</offsets></p><p><offsets xml_i="11547" xml_f="11688" txt_i="2110" txt_f="2251">Oral anticoagulation therapy (OAC) with vitamin K antagonists reduces the risk of stroke and systemic embolism by ≈80% compared with placebo.</offsets><xref rid="jah31637-bib-0006" ref-type="ref"><offsets xml_i="11733" xml_f="11734" txt_i="2251" txt_f="2252">6</offsets></xref><offsets xml_i="11741" xml_f="11958" txt_i="2252" txt_f="2469"> The direct oral anticoagulants are at least as effective as vitamin K antagonists. However, direct oral anticoagulants confer improved safety as compared with vitamin K antagonists in terms of bleeding complications.</offsets><xref rid="jah31637-bib-0007" ref-type="ref"><offsets xml_i="12003" xml_f="12004" txt_i="2469" txt_f="2470">7</offsets></xref><offsets xml_i="12011" xml_f="12013" txt_i="2470" txt_f="2472">, </offsets><xref rid="jah31637-bib-0008" ref-type="ref"><offsets xml_i="12058" xml_f="12059" txt_i="2472" txt_f="2473">8</offsets></xref><offsets xml_i="12066" xml_f="12068" txt_i="2473" txt_f="2475">, </offsets><xref rid="jah31637-bib-0009" ref-type="ref"><offsets xml_i="12113" xml_f="12114" txt_i="2475" txt_f="2476">9</offsets></xref><offsets xml_i="12121" xml_f="12123" txt_i="2476" txt_f="2478">, </offsets><xref rid="jah31637-bib-0010" ref-type="ref"><offsets xml_i="12168" xml_f="12170" txt_i="2478" txt_f="2480">10</offsets></xref><offsets xml_i="12177" xml_f="12178" txt_i="2480" txt_f="2481">
</offsets></p><p><offsets xml_i="12185" xml_f="12350" txt_i="2482" txt_f="2647">Current guidelines of the American Heart Association, the American College of Cardiology, and the European Society of Cardiology recommend the calculation of the CHA</offsets><sub><offsets xml_i="12355" xml_f="12356" txt_i="2647" txt_f="2648">2</offsets></sub><offsets xml_i="12362" xml_f="12364" txt_i="2648" txt_f="2650">DS</offsets><sub><offsets xml_i="12369" xml_f="12370" txt_i="2650" txt_f="2651">2</offsets></sub><offsets xml_i="12376" xml_f="12412" txt_i="2651" txt_f="2687">‐VASc score in all patients with AF.</offsets><xref rid="jah31637-bib-0006" ref-type="ref"><offsets xml_i="12457" xml_f="12458" txt_i="2687" txt_f="2688">6</offsets></xref><offsets xml_i="12465" xml_f="12467" txt_i="2688" txt_f="2690">, </offsets><xref rid="jah31637-bib-0011" ref-type="ref"><offsets xml_i="12512" xml_f="12514" txt_i="2690" txt_f="2692">11</offsets></xref><offsets xml_i="12521" xml_f="12689" txt_i="2692" txt_f="2860"> In patients with a score of ≥1 point with the exception of women without additional risk factor, OAC is recommended for the prevention of stroke and systemic embolism.</offsets><xref rid="jah31637-bib-0011" ref-type="ref"><offsets xml_i="12734" xml_f="12736" txt_i="2860" txt_f="2862">11</offsets></xref><offsets xml_i="12743" xml_f="12824" txt_i="2862" txt_f="2943"> However, many patients with AF do not take OAC as recommended by the guidelines.</offsets><xref rid="jah31637-bib-0012" ref-type="ref"><offsets xml_i="12869" xml_f="12871" txt_i="2943" txt_f="2945">12</offsets></xref><offsets xml_i="12878" xml_f="12879" txt_i="2945" txt_f="2946">
</offsets></p><p><offsets xml_i="12886" xml_f="12982" txt_i="2947" txt_f="3043">Undertreatment can be reduced by increasing adherence rates to medications at the patient level.</offsets><xref rid="jah31637-bib-0013" ref-type="ref"><offsets xml_i="13027" xml_f="13029" txt_i="3043" txt_f="3045">13</offsets></xref><offsets xml_i="13036" xml_f="13351" txt_i="3045" txt_f="3360"> However, better quality of treatment may also be achieved by making the physicians in charge aware of a problem that needs to be addressed. In this respect, computer‐based electronic alert systems or clinical decision support systems may improve the prescription of recommended therapy among hospitalized patients.</offsets><xref rid="jah31637-bib-0014" ref-type="ref"><offsets xml_i="13396" xml_f="13398" txt_i="3360" txt_f="3362">14</offsets></xref><offsets xml_i="13405" xml_f="13407" txt_i="3362" txt_f="3364">, </offsets><xref rid="jah31637-bib-0015" ref-type="ref"><offsets xml_i="13452" xml_f="13454" txt_i="3364" txt_f="3366">15</offsets></xref><offsets xml_i="13461" xml_f="13462" txt_i="3366" txt_f="3367">
</offsets></p><p><offsets xml_i="13469" xml_f="13684" txt_i="3368" txt_f="3583">In a randomized controlled clinical trial, a single computer alert to the physician in charge increased the rate of adequate prescriptions of thromboprophylaxis and reduced the rate of venous thromboembolism by 41%.</offsets><xref rid="jah31637-bib-0016" ref-type="ref"><offsets xml_i="13729" xml_f="13731" txt_i="3583" txt_f="3585">16</offsets></xref><offsets xml_i="13738" xml_f="13871" txt_i="3585" txt_f="3718"> It remains unclear whether computer‐based electronic alert systems improve adequate OAC prescription among hospitalized AF patients.</offsets></p></sec><sec id="jah31637-sec-0006"><title><offsets xml_i="13916" xml_f="13923" txt_i="3720" txt_f="3727">Methods</offsets></title><sec id="jah31637-sec-0007"><title><offsets xml_i="13966" xml_f="13978" txt_i="3728" txt_f="3740">Alert System</offsets></title><p><offsets xml_i="13989" xml_f="14194" txt_i="3741" txt_f="3946">We developed a computer‐based electronic alert system for identifying consecutive hospitalized OAC‐naïve patients with AF and tested the hypothesis that such an alert system would improve OAC prescription.</offsets></p><p><offsets xml_i="14201" xml_f="15421" txt_i="3947" txt_f="5167">The alert system automatically identified hospitalized patients with AF without an active OAC prescription in the electronic order entry system. The alert system was incorporated into the electronic medical chart and order entry system of the University Hospital in Bern, Switzerland. It recognized AF by permanently searching diagnosis lists and physician notes of the entire electronic patient chart database for free text entries of AF or its various abbreviations. Alerts were issued 24 hours after the onset of hospital stay if the following 4 criteria for an individual patient were present: (1) AF detected by search criteria; (2) no active prescription order for anticoagulants, including unfractionated or low‐molecular‐weight heparin, fondaparinux, direct oral anticoagulants, or vitamin K antagonists; (3) at least 1 electronic drug prescription order other than an anticoagulant had to be in place in the order entry system; and (4) the patient was randomized to the alert group. Once the criteria were fulfilled, the alert was issued in the electronic patient chart. The alert was visible to physicians and nurses, but only physicians were enabled to respond to the alert. In the first alert screen (Figure </offsets><xref rid="jah31637-fig-0001" ref-type="fig"><offsets xml_i="15466" xml_f="15467" txt_i="5167" txt_f="5168">1</offsets></xref><offsets xml_i="15474" xml_f="15701" txt_i="5168" txt_f="5395">), the physician was notified that this patient had suspected AF without an active OAC prescription. In addition, the physician was asked to confirm the presence of AF. The physician in charge had the option to complete the CHA</offsets><sub><offsets xml_i="15706" xml_f="15707" txt_i="5395" txt_f="5396">2</offsets></sub><offsets xml_i="15713" xml_f="15715" txt_i="5396" txt_f="5398">DS</offsets><sub><offsets xml_i="15720" xml_f="15721" txt_i="5398" txt_f="5399">2</offsets></sub><offsets xml_i="15727" xml_f="15863" txt_i="5399" txt_f="5535">‐VASc score electronically or to reject the alert if there was no AF. If AF was present but the physician was unable to complete the CHA</offsets><sub><offsets xml_i="15868" xml_f="15869" txt_i="5535" txt_f="5536">2</offsets></sub><offsets xml_i="15875" xml_f="15877" txt_i="5536" txt_f="5538">DS</offsets><sub><offsets xml_i="15882" xml_f="15883" txt_i="5538" txt_f="5539">2</offsets></sub><offsets xml_i="15889" xml_f="16205" txt_i="5539" txt_f="5855">‐VASc score, he or she was able to postpone the action 3 times. During this time, the alert remained active. After 3 times of rejecting the alert, the physician in charge was informed that the alert would permanently disappear from the electronic patient chart. If the physician in charge agreed to calculate the CHA</offsets><sub><offsets xml_i="16210" xml_f="16211" txt_i="5855" txt_f="5856">2</offsets></sub><offsets xml_i="16217" xml_f="16219" txt_i="5856" txt_f="5858">DS</offsets><sub><offsets xml_i="16224" xml_f="16225" txt_i="5858" txt_f="5859">2</offsets></sub><offsets xml_i="16231" xml_f="16269" txt_i="5859" txt_f="5897">‐VASc score, a new screen with the CHA</offsets><sub><offsets xml_i="16274" xml_f="16275" txt_i="5897" txt_f="5898">2</offsets></sub><offsets xml_i="16281" xml_f="16283" txt_i="5898" txt_f="5900">DS</offsets><sub><offsets xml_i="16288" xml_f="16289" txt_i="5900" txt_f="5901">2</offsets></sub><offsets xml_i="16295" xml_f="16692" txt_i="5901" txt_f="6292">‐VASc score items opened (Figure S1). The system automatically entered the information for the score items sex and age. The system also calculated the score once the remaining items of the score were entered. In men with a calculated score &lt;1 and women with a score &lt;2, no further information was provided to the physician and the alert disappeared. For all other patients with increased CHA</offsets><sub><offsets xml_i="16697" xml_f="16698" txt_i="6292" txt_f="6293">2</offsets></sub><offsets xml_i="16704" xml_f="16706" txt_i="6293" txt_f="6295">DS</offsets><sub><offsets xml_i="16711" xml_f="16712" txt_i="6295" txt_f="6296">2</offsets></sub><offsets xml_i="16718" xml_f="16905" txt_i="6296" txt_f="6483">‐VASc score, an additional screen opened, containing the current recommendations from the European Society of Cardiology for stroke prevention in patients with AF with the following text.</offsets><xref rid="jah31637-bib-0011" ref-type="ref"><offsets xml_i="16950" xml_f="16952" txt_i="6483" txt_f="6485">11</offsets></xref><offsets xml_i="16959" xml_f="16960" txt_i="6485" txt_f="6486">
</offsets></p><fig fig-type="Figure" xml:lang="en" id="jah31637-fig-0001" orientation="portrait" position="float"><label><offsets xml_i="17071" xml_f="17079" txt_i="6487" txt_f="6495">Figure 1</offsets></label><caption><p><offsets xml_i="17099" xml_f="17240" txt_i="6495" txt_f="6636">Electronic alert screen that is sent to physicians in charge of patients with atrial fibrillation but without oral anticoagulation treatment.</offsets></p></caption><graphic id="nlm-graphic-1" xlink:href="JAH3-5-e003776-g001"></graphic></fig><p><offsets xml_i="17334" xml_f="17706" txt_i="6637" txt_f="7009">The alert system was tested and adjusted in a passive run‐in phase in collaboration with the IT Department of the University Hospital (Inselspital) Bern. Instructions for use of the alert system were provided in the electronic medical chart and order entry system. In addition, the heads of the medical departments were asked to inform their medical staff about the study.</offsets></p></sec><sec id="jah31637-sec-0008"><title><offsets xml_i="17751" xml_f="17763" txt_i="7011" txt_f="7023">Study Design</offsets></title><p><offsets xml_i="17774" xml_f="18247" txt_i="7024" txt_f="7497">From September 2014 until October 2015 at the University Hospital Bern, we randomly assigned 1707 patients in a 1:1 fashion to the alert group (n=877) and to the control group (n=830) where no alert was issued. Randomization was performed electronically by automatically generating a number between 1 and 65 535 for each eligible patient. Patients with odd numbers were randomized to the alert group, whereas patients with even numbers were randomized to the control group.</offsets></p><p><offsets xml_i="18254" xml_f="18416" txt_i="7498" txt_f="7660">All hospitalized patients aged ≥18 years with AF but without an active OAC prescription in the order entry system were included. There were no exclusion criteria.</offsets></p><p><offsets xml_i="18423" xml_f="18434" txt_i="7661" txt_f="7672">The study (</offsets><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov"><offsets xml_i="18503" xml_f="18521" txt_i="7672" txt_f="7690">ClinicalTrials.gov</offsets></ext-link><offsets xml_i="18532" xml_f="19530" txt_i="7690" txt_f="8688">. Identifier: NCT02455102) was approved by the institutional review board at the University of Bern. Informed consent by the patients was waived for the following reasons: (1) The study did not involve an intervention to patients but to physicians. The intervention served to remind the responsible physician to assess the stroke risk in patients with AF and to consider the prescription of preventive measures if an increased risk of stroke was present. Therefore, the alert was regarded as a clinical decision support system to help the physician to comply with current international consensus guidelines. However, the responsible physician solely carried the responsibility for ordering or not ordering measures to prevent stroke in patients with AF; (2) there was no direct or indirect patient contact during the study (chart review from the hospital stay only; and (3) a consent procedure in control group patients without alert was regarded as unethical and would have confounded the outcome.</offsets></p><p><offsets xml_i="19537" xml_f="19703" txt_i="8689" txt_f="8855">As this was a hospital‐wide quality improvement initiative, which involved all departments except pediatrics, approval was also obtained from the hospital management.</offsets></p></sec><sec id="jah31637-sec-0009"><title><offsets xml_i="19748" xml_f="19758" txt_i="8857" txt_f="8867">End Points</offsets></title><p><offsets xml_i="19769" xml_f="19958" txt_i="8868" txt_f="9057">The primary end point of the study was the rate of adequate OAC prescription at hospital discharge, defined as prescription of any of the recommended drug regimens in OAC‐naïve men with CHA</offsets><sub><offsets xml_i="19963" xml_f="19964" txt_i="9057" txt_f="9058">2</offsets></sub><offsets xml_i="19970" xml_f="19972" txt_i="9058" txt_f="9060">DS</offsets><sub><offsets xml_i="19977" xml_f="19978" txt_i="9060" txt_f="9061">2</offsets></sub><offsets xml_i="19984" xml_f="20030" txt_i="9061" txt_f="9107">‐VASc score ≥1 and in OAC‐naïve women with CHA</offsets><sub><offsets xml_i="20035" xml_f="20036" txt_i="9107" txt_f="9108">2</offsets></sub><offsets xml_i="20042" xml_f="20044" txt_i="9108" txt_f="9110">DS</offsets><sub><offsets xml_i="20049" xml_f="20050" txt_i="9110" txt_f="9111">2</offsets></sub><offsets xml_i="20056" xml_f="20223" txt_i="9111" txt_f="9278">‐VASc score ≥2. Patients were considered OAC‐naïve if they were not receiving OAC within 30 days prior to randomization. The secondary end point was the use of the CHA</offsets><sub><offsets xml_i="20228" xml_f="20229" txt_i="9278" txt_f="9279">2</offsets></sub><offsets xml_i="20235" xml_f="20237" txt_i="9279" txt_f="9281">DS</offsets><sub><offsets xml_i="20242" xml_f="20243" txt_i="9281" txt_f="9282">2</offsets></sub><offsets xml_i="20249" xml_f="20566" txt_i="9282" txt_f="9599">‐VASc score calculation tool by the physician in charge. We also collected data to calculate the HASBLED score. This score indicates bleeding risk and includes the risk factors hypertension, abnormal renal or liver function, stroke, bleeding history or predisposition, labile INR, elderly, and drugs or alcohol abuse.</offsets><xref rid="jah31637-bib-0017" ref-type="ref"><offsets xml_i="20611" xml_f="20613" txt_i="9599" txt_f="9601">17</offsets></xref><offsets xml_i="20620" xml_f="20621" txt_i="9601" txt_f="9602">
</offsets></p></sec><sec id="jah31637-sec-0010"><title><offsets xml_i="20666" xml_f="20686" txt_i="9604" txt_f="9624">Statistical Analysis</offsets></title><p><offsets xml_i="20697" xml_f="21257" txt_i="9625" txt_f="10185">For sample size calculation, we assumed a 30% rate of adequate OAC prescription in the alert group and a 20% rate in the control group. Using a power of 90% and a 2‐sided alpha of 5%, at least 412 OAC‐naïve AF patients per group were required to reject the null hypothesis. During the recruitment phase, we continuously monitored all randomized patients whether they were OAC naïve and had confirmed AF by medical record review. We planned to terminate the patient recruitment phase once at least 412 OAC‐naïve AF patients per group were eligible for analysis.</offsets></p><p><offsets xml_i="21264" xml_f="21480" txt_i="10186" txt_f="10402">Data for baseline characteristics and the primary and secondary end points are presented as absolute numbers and percentages or as means and standard deviations for categorical or continuous variables, respectively. </offsets><italic><offsets xml_i="21488" xml_f="21489" txt_i="10402" txt_f="10403">P</offsets></italic><offsets xml_i="21498" xml_f="21588" txt_i="10403" txt_f="10493">‐values for differences between the groups with regard to end points are calculated with χ</offsets><sup><offsets xml_i="21593" xml_f="21594" txt_i="10493" txt_f="10494">2</offsets></sup><offsets xml_i="21600" xml_f="21612" txt_i="10494" txt_f="10506"> tests. All </offsets><italic><offsets xml_i="21620" xml_f="21621" txt_i="10506" txt_f="10507">P</offsets></italic><offsets xml_i="21630" xml_f="21654" txt_i="10507" txt_f="10531">‐values are 2‐sided and </offsets><italic><offsets xml_i="21662" xml_f="21663" txt_i="10531" txt_f="10532">P</offsets></italic><offsets xml_i="21672" xml_f="21971" txt_i="10532" txt_f="10828">‐values &lt;0.05 were considered significant. For the primary end point, we additionally calculated the relative risk for ordering adequate OAC prescription comparing the alert and control groups. All analyses were performed with IBM SPSS Statistics for Windows, Version 21.0 (IBM Corp, Armonk, NY).</offsets></p></sec></sec><sec id="jah31637-sec-0011"><title><offsets xml_i="22022" xml_f="22029" txt_i="10831" txt_f="10838">Results</offsets></title><sec id="jah31637-sec-0012"><title><offsets xml_i="22072" xml_f="22095" txt_i="10839" txt_f="10862">Patient Characteristics</offsets></title><p><offsets xml_i="22106" xml_f="22178" txt_i="10863" txt_f="10935">A total of 889 OAC‐naïve AF patients were eligible for analysis (Figure </offsets><xref rid="jah31637-fig-0002" ref-type="fig"><offsets xml_i="22223" xml_f="22224" txt_i="10935" txt_f="10936">2</offsets></xref><offsets xml_i="22231" xml_f="22714" txt_i="10936" txt_f="11419">). Mean (SD) age was 73.9 (11.3) years. Overall, 359 (40.3%), 48 (5.4%), and 31 (3.5%) patients had paroxysmal, permanent, and persistent AF, respectively, whereas in 451 (50.7%) patients, the type of AF was unknown. Both groups were balanced with respect to baseline characteristics with the exception of a higher rate of systemic hypertension, a trend toward a higher rate of transient ischemic attack, and a trend toward a lower rate of renal dysfunction in the alert group (Table</offsets><italic><offsets xml_i="22722" xml_f="22723" txt_i="11419" txt_f="11420"> </offsets></italic><offsets xml_i="22732" xml_f="22733" txt_i="11420" txt_f="11421">
</offsets><xref rid="jah31637-tbl-0001" ref-type="table-wrap"><offsets xml_i="22785" xml_f="22786" txt_i="11421" txt_f="11422">1</offsets></xref><offsets xml_i="22793" xml_f="23008" txt_i="11422" txt_f="11637">). The most frequent reasons for hospital admission were acute coronary syndrome or other cardiovascular disease (30.0%), cancer (10.6%), nonpulmonary infection (7.9%), stroke (6.9%), and heart failure (6.4%) (Table</offsets><italic><offsets xml_i="23016" xml_f="23017" txt_i="11637" txt_f="11638"> </offsets></italic><offsets xml_i="23026" xml_f="23027" txt_i="11638" txt_f="11639">
</offsets><xref rid="jah31637-tbl-0002" ref-type="table-wrap"><offsets xml_i="23079" xml_f="23080" txt_i="11639" txt_f="11640">2</offsets></xref><offsets xml_i="23087" xml_f="23149" txt_i="11640" txt_f="11702">). The mean duration of the hospital stay was 9.4 (10.8) days.</offsets></p><fig fig-type="Figure" xml:lang="en" id="jah31637-fig-0002" orientation="portrait" position="float"><label><offsets xml_i="23260" xml_f="23268" txt_i="11703" txt_f="11711">Figure 2</offsets></label><caption><p><offsets xml_i="23288" xml_f="23538" txt_i="11711" txt_f="11961">Flow chart of the patients whose physicians in charge received electronic alerts reminding them about patients with atrial fibrillation without ongoing oral anticoagulant treatment. AF indicates atrial fibrillation; OAC, oral anticoagulation therapy.</offsets></p></caption><graphic id="nlm-graphic-3" xlink:href="JAH3-5-e003776-g002"></graphic></fig><table-wrap id="jah31637-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label><offsets xml_i="23725" xml_f="23732" txt_i="11962" txt_f="11969">Table 1</offsets></label><caption><p><offsets xml_i="23752" xml_f="23836" txt_i="11969" txt_f="12053">Clinical Baseline Characteristics of the Patients Stratified for Randomization Group</offsets></p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"></col><col style="border-right:solid 1px #000000" span="1"></col><col style="border-right:solid 1px #000000" span="1"></col><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"></th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1"><offsets xml_i="24281" xml_f="24300" txt_i="12054" txt_f="12073">Randomization Group</offsets></th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="24408" xml_f="24415" txt_i="12073" txt_f="12080">Control</offsets></th><th align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="24474" xml_f="24479" txt_i="12080" txt_f="12085">Alert</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="24549" xml_f="24555" txt_i="12085" txt_f="12091">Number</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="24601" xml_f="24604" txt_i="12092" txt_f="12095">434</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="24650" xml_f="24653" txt_i="12096" txt_f="12099">455</offsets></td></tr><tr><td align="left" colspan="3" rowspan="1"><offsets xml_i="24708" xml_f="24711" txt_i="12100" txt_f="12103">Sex</offsets></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><offsets xml_i="24791" xml_f="24795" txt_i="12104" txt_f="12108">Male</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="24841" xml_f="24851" txt_i="12109" txt_f="12119">292 (67.3)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="24897" xml_f="24907" txt_i="12120" txt_f="12130">300 (65.9)</offsets></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><offsets xml_i="24987" xml_f="24993" txt_i="12131" txt_f="12137">Female</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25039" xml_f="25049" txt_i="12138" txt_f="12148">142 (32.7)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25095" xml_f="25105" txt_i="12149" txt_f="12159">155 (34.1)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="25160" xml_f="25167" txt_i="12160" txt_f="12167">Age (y)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25213" xml_f="25224" txt_i="12168" txt_f="12179">73.3 (11.8)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25270" xml_f="25281" txt_i="12180" txt_f="12191">74.4 (10.9)</offsets></td></tr><tr><td align="left" colspan="3" rowspan="1"><offsets xml_i="25336" xml_f="25363" txt_i="12192" txt_f="12219">Type of atrial fibrillation</offsets></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><offsets xml_i="25443" xml_f="25453" txt_i="12220" txt_f="12230">Paroxysmal</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25499" xml_f="25509" txt_i="12231" txt_f="12241">174 (40.1)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25555" xml_f="25565" txt_i="12242" txt_f="12252">185 (40.7)</offsets></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><offsets xml_i="25645" xml_f="25654" txt_i="12253" txt_f="12262">Permanent</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25700" xml_f="25708" txt_i="12263" txt_f="12271">25 (5.8)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25754" xml_f="25762" txt_i="12272" txt_f="12280">23 (5.1)</offsets></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><offsets xml_i="25842" xml_f="25852" txt_i="12281" txt_f="12291">Persistent</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25898" xml_f="25906" txt_i="12292" txt_f="12300">15 (3.5)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25952" xml_f="25960" txt_i="12301" txt_f="12309">16 (3.5)</offsets></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><offsets xml_i="26040" xml_f="26047" txt_i="12310" txt_f="12317">Unknown</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="26093" xml_f="26103" txt_i="12318" txt_f="12328">220 (50.7)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="26149" xml_f="26159" txt_i="12329" txt_f="12339">231 (50.8)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="26214" xml_f="26231" txt_i="12340" txt_f="12357">History of stroke</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="26277" xml_f="26285" txt_i="12358" txt_f="12366">27 (6.2)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="26331" xml_f="26339" txt_i="12367" txt_f="12375">41 (9.0)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="26394" xml_f="26430" txt_i="12376" txt_f="12412">History of transient ischemic attack</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="26476" xml_f="26484" txt_i="12413" txt_f="12421">13 (3.0)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="26530" xml_f="26538" txt_i="12422" txt_f="12430">26 (5.7)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="26593" xml_f="26626" txt_i="12431" txt_f="12464">History of venous thromboembolism</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="26672" xml_f="26680" txt_i="12465" txt_f="12473">25 (5.8)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="26726" xml_f="26734" txt_i="12474" txt_f="12482">35 (7.7)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="26789" xml_f="26817" txt_i="12483" txt_f="12511">History of systemic embolism</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="26863" xml_f="26870" txt_i="12512" txt_f="12519">4 (0.9)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="26916" xml_f="26923" txt_i="12520" txt_f="12527">3 (0.7)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="26978" xml_f="26994" txt_i="12528" txt_f="12544">Vascular disease</offsets><xref ref-type="fn" rid="jah31637-note-0003"><offsets xml_i="27039" xml_f="27040" txt_i="12544" txt_f="12545">a</offsets></xref><offsets xml_i="27047" xml_f="27048" txt_i="12545" txt_f="12546">
</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27094" xml_f="27104" txt_i="12547" txt_f="12557">154 (35.5)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27150" xml_f="27160" txt_i="12558" txt_f="12568">179 (39.3)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="27215" xml_f="27239" txt_i="12569" txt_f="12593">Congestive heart failure</offsets><xref ref-type="fn" rid="jah31637-note-0004"><offsets xml_i="27284" xml_f="27285" txt_i="12593" txt_f="12594">b</offsets></xref><offsets xml_i="27292" xml_f="27293" txt_i="12594" txt_f="12595">
</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27339" xml_f="27349" txt_i="12596" txt_f="12606">134 (30.9)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27395" xml_f="27405" txt_i="12607" txt_f="12617">137 (30.1)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="27460" xml_f="27477" txt_i="12618" txt_f="12635">Diabetes mellitus</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27523" xml_f="27532" txt_i="12636" txt_f="12645">93 (21.4)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27578" xml_f="27588" txt_i="12646" txt_f="12656">104 (22.9)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="27643" xml_f="27664" txt_i="12657" txt_f="12678">Systemic hypertension</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27710" xml_f="27720" txt_i="12679" txt_f="12689">229 (52.8)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27766" xml_f="27776" txt_i="12690" txt_f="12700">276 (60.7)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="27831" xml_f="27839" txt_i="12701" txt_f="12709">Bleeding</offsets><xref ref-type="fn" rid="jah31637-note-0005"><offsets xml_i="27884" xml_f="27885" txt_i="12709" txt_f="12710">c</offsets></xref><offsets xml_i="27892" xml_f="27893" txt_i="12710" txt_f="12711">
</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27939" xml_f="27949" txt_i="12712" txt_f="12722">143 (32.9)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27995" xml_f="28005" txt_i="12723" txt_f="12733">140 (30.8)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="28060" xml_f="28077" txt_i="12734" txt_f="12751">Renal dysfunction</offsets><xref ref-type="fn" rid="jah31637-note-0006"><offsets xml_i="28122" xml_f="28123" txt_i="12751" txt_f="12752">d</offsets></xref><offsets xml_i="28130" xml_f="28131" txt_i="12752" txt_f="12753">
</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="28177" xml_f="28187" txt_i="12754" txt_f="12764">100 (23.0)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="28233" xml_f="28242" txt_i="12765" txt_f="12774">80 (17.6)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="28297" xml_f="28315" txt_i="12775" txt_f="12793">Hepatic impairment</offsets><xref ref-type="fn" rid="jah31637-note-0007"><offsets xml_i="28360" xml_f="28361" txt_i="12793" txt_f="12794">e</offsets></xref><offsets xml_i="28368" xml_f="28369" txt_i="12794" txt_f="12795">
</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="28415" xml_f="28423" txt_i="12796" txt_f="12804">16 (3.7)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="28469" xml_f="28477" txt_i="12805" txt_f="12813">15 (3.3)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="28532" xml_f="28546" txt_i="12814" txt_f="12828">Alcohol intake</offsets><xref ref-type="fn" rid="jah31637-note-0008"><offsets xml_i="28591" xml_f="28592" txt_i="12828" txt_f="12829">f</offsets></xref><offsets xml_i="28599" xml_f="28600" txt_i="12829" txt_f="12830">
</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="28646" xml_f="28654" txt_i="12831" txt_f="12839">23 (5.3)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="28700" xml_f="28708" txt_i="12840" txt_f="12848">20 (4.4)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="28763" xml_f="28810" txt_i="12849" txt_f="12896">Antiplatelet or nonsteroidal antirheumatic drug</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="28856" xml_f="28866" txt_i="12897" txt_f="12907">235 (54.1)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="28912" xml_f="28922" txt_i="12908" txt_f="12918">265 (58.2)</offsets></td></tr></tbody></table><table-wrap-foot><fn id="jah31637-note-0002"><p><offsets xml_i="28996" xml_f="29105" txt_i="12919" txt_f="13028">Values are numbers and percentages for categorical data or means with standard deviation for continuous data.</offsets></p></fn><fn id="jah31637-note-0003"><label><offsets xml_i="29149" xml_f="29150" txt_i="13029" txt_f="13030">a</offsets></label><p><offsets xml_i="29161" xml_f="29228" txt_i="13030" txt_f="13097">Myocardial infarction, peripheral artery disease, or aortic plaque.</offsets></p></fn><fn id="jah31637-note-0004"><label><offsets xml_i="29272" xml_f="29273" txt_i="13098" txt_f="13099">b</offsets></label><p><offsets xml_i="29284" xml_f="29349" txt_i="13099" txt_f="13164">Chronic heart failure or left ventricular ejection fraction ≤40%.</offsets></p></fn><fn id="jah31637-note-0005"><label><offsets xml_i="29393" xml_f="29394" txt_i="13165" txt_f="13166">c</offsets></label><p><offsets xml_i="29405" xml_f="29459" txt_i="13166" txt_f="13220">History of major bleeding and predisposition (anemia).</offsets></p></fn><fn id="jah31637-note-0006"><label><offsets xml_i="29503" xml_f="29504" txt_i="13221" txt_f="13222">d</offsets></label><p><offsets xml_i="29515" xml_f="29550" txt_i="13222" txt_f="13254">Creatinine clearance &lt;30 mL/min.</offsets></p></fn><fn id="jah31637-note-0007"><label><offsets xml_i="29594" xml_f="29595" txt_i="13255" txt_f="13256">e</offsets></label><p><offsets xml_i="29606" xml_f="29652" txt_i="13256" txt_f="13299">Aminotransferase &gt;3× upper limit of normal.</offsets></p></fn><fn id="jah31637-note-0008"><label><offsets xml_i="29696" xml_f="29697" txt_i="13300" txt_f="13301">f</offsets></label><p><offsets xml_i="29708" xml_f="29738" txt_i="13301" txt_f="13331">≥Eight units alcohol per week.</offsets></p></fn></table-wrap-foot></table-wrap><table-wrap id="jah31637-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label><offsets xml_i="29874" xml_f="29881" txt_i="13332" txt_f="13339">Table 2</offsets></label><caption><p><offsets xml_i="29901" xml_f="29996" txt_i="13339" txt_f="13434">Diagnoses, Which Were the Main Reason for Hospital Admission, Stratified by Randomization Group</offsets></p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"></col><col style="border-right:solid 1px #000000" span="1"></col><col style="border-right:solid 1px #000000" span="1"></col><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"><offsets xml_i="30342" xml_f="30348" txt_i="13435" txt_f="13441">Reason</offsets></th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1"><offsets xml_i="30447" xml_f="30452" txt_i="13441" txt_f="13446">Group</offsets></th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="30560" xml_f="30567" txt_i="13446" txt_f="13453">Control</offsets></th><th align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="30626" xml_f="30631" txt_i="13453" txt_f="13458">Alert</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="30701" xml_f="30739" txt_i="13458" txt_f="13496">Cardiovascular disease/rhythm disorder</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="30785" xml_f="30795" txt_i="13497" txt_f="13507">129 (29.7)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="30841" xml_f="30851" txt_i="13508" txt_f="13518">138 (30.3)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="30906" xml_f="30937" txt_i="13519" txt_f="13550">Heart failure (NYHA III and IV)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="30983" xml_f="30991" txt_i="13551" txt_f="13559">31 (7.1)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="31037" xml_f="31045" txt_i="13560" txt_f="13568">26 (5.7)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="31100" xml_f="31138" txt_i="13569" txt_f="13607">Acute stroke (ischemic or hemorrhagic)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="31184" xml_f="31192" txt_i="13608" txt_f="13616">27 (6.2)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="31238" xml_f="31246" txt_i="13617" txt_f="13625">35 (7.7)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="31301" xml_f="31307" txt_i="13626" txt_f="13632">Cancer</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="31353" xml_f="31362" txt_i="13633" txt_f="13642">48 (11.1)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="31408" xml_f="31417" txt_i="13643" txt_f="13652">46 (10.1)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="31472" xml_f="31504" txt_i="13653" txt_f="13685">Nonpulmonary infection or sepsis</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="31550" xml_f="31558" txt_i="13686" txt_f="13694">35 (8.1)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="31604" xml_f="31612" txt_i="13695" txt_f="13703">35 (7.7)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="31667" xml_f="31692" txt_i="13704" txt_f="13729">Gastrointestinal bleeding</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="31738" xml_f="31746" txt_i="13730" txt_f="13738">11 (2.5)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="31792" xml_f="31799" txt_i="13739" txt_f="13746">6 (1.3)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="31854" xml_f="31863" txt_i="13747" txt_f="13756">Pneumonia</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="31909" xml_f="31916" txt_i="13757" txt_f="13764">8 (1.8)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="31962" xml_f="31969" txt_i="13765" txt_f="13772">6 (1.3)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="32024" xml_f="32028" txt_i="13773" txt_f="13777">COPD</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32074" xml_f="32081" txt_i="13778" txt_f="13785">3 (0.7)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32127" xml_f="32134" txt_i="13786" txt_f="13793">0 (0.0)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="32189" xml_f="32202" txt_i="13794" txt_f="13807">Renal failure</offsets><xref ref-type="fn" rid="jah31637-note-0010"><offsets xml_i="32247" xml_f="32248" txt_i="13807" txt_f="13808">a</offsets></xref><offsets xml_i="32255" xml_f="32256" txt_i="13808" txt_f="13809">
</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32302" xml_f="32309" txt_i="13810" txt_f="13817">8 (1.8)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32355" xml_f="32362" txt_i="13818" txt_f="13825">5 (1.1)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="32417" xml_f="32450" txt_i="13826" txt_f="13859">Inflammatory or rheumatic disease</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32496" xml_f="32503" txt_i="13860" txt_f="13867">4 (0.9)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32549" xml_f="32556" txt_i="13868" txt_f="13875">4 (0.9)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="32611" xml_f="32651" txt_i="13876" txt_f="13916">Liver cirrhosis or hepatobiliary disease</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32697" xml_f="32704" txt_i="13917" txt_f="13924">2 (0.5)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32750" xml_f="32757" txt_i="13925" txt_f="13932">7 (1.5)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="32812" xml_f="32850" txt_i="13933" txt_f="13971">Endocrine disease (including diabetes)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32896" xml_f="32903" txt_i="13972" txt_f="13979">1 (0.2)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32949" xml_f="32956" txt_i="13980" txt_f="13987">3 (0.7)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="33011" xml_f="33047" txt_i="13988" txt_f="14024">Hematological disease (nonmalignant)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="33093" xml_f="33100" txt_i="14025" txt_f="14032">0 (0.0)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="33146" xml_f="33153" txt_i="14033" txt_f="14040">1 (0.2)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="33208" xml_f="33231" txt_i="14041" txt_f="14064">Other medical condition</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="33277" xml_f="33287" txt_i="14065" txt_f="14075">127 (29.3)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="33333" xml_f="33343" txt_i="14076" txt_f="14086">143 (31.4)</offsets></td></tr></tbody></table><table-wrap-foot><fn id="jah31637-note-0009"><p><offsets xml_i="33417" xml_f="33540" txt_i="14087" txt_f="14210">Values are numbers and percentages. COPD indicates chronic obstructive pulmonary disease; NYHA, New York Heart Association.</offsets></p></fn><fn id="jah31637-note-0010"><label><offsets xml_i="33584" xml_f="33585" txt_i="14211" txt_f="14212">a</offsets></label><p><offsets xml_i="33596" xml_f="33631" txt_i="14212" txt_f="14244">Creatinine clearance &lt;30 mL/min.</offsets></p></fn></table-wrap-foot></table-wrap><p><offsets xml_i="33674" xml_f="33701" txt_i="14245" txt_f="14272">Very few patients had a CHA</offsets><sub><offsets xml_i="33706" xml_f="33707" txt_i="14272" txt_f="14273">2</offsets></sub><offsets xml_i="33713" xml_f="33715" txt_i="14273" txt_f="14275">DS</offsets><sub><offsets xml_i="33720" xml_f="33721" txt_i="14275" txt_f="14276">2</offsets></sub><offsets xml_i="33727" xml_f="33784" txt_i="14276" txt_f="14333">‐VASC score of 0, and there were only 10 women with a CHA</offsets><sub><offsets xml_i="33789" xml_f="33790" txt_i="14333" txt_f="14334">2</offsets></sub><offsets xml_i="33796" xml_f="33798" txt_i="14334" txt_f="14336">DS</offsets><sub><offsets xml_i="33803" xml_f="33804" txt_i="14336" txt_f="14337">2</offsets></sub><offsets xml_i="33810" xml_f="33912" txt_i="14337" txt_f="14439">‐VASC score of 1 (Table S1). Overall, 856 (96.3%) of the patients were OAC candidates based on the CHA</offsets><sub><offsets xml_i="33917" xml_f="33918" txt_i="14439" txt_f="14440">2</offsets></sub><offsets xml_i="33924" xml_f="33926" txt_i="14440" txt_f="14442">DS</offsets><sub><offsets xml_i="33931" xml_f="33932" txt_i="14442" txt_f="14443">2</offsets></sub><offsets xml_i="33938" xml_f="34027" txt_i="14443" txt_f="14532">‐VASC score. There was no difference in the proportion of OAC candidates based on the CHA</offsets><sub><offsets xml_i="34032" xml_f="34033" txt_i="14532" txt_f="14533">2</offsets></sub><offsets xml_i="34039" xml_f="34041" txt_i="14533" txt_f="14535">DS</offsets><sub><offsets xml_i="34046" xml_f="34047" txt_i="14535" txt_f="14536">2</offsets></sub><offsets xml_i="34053" xml_f="34133" txt_i="14536" txt_f="14616">‐VASC score between the alert (443; 97.4%) and the control (413; 95.2%) groups (</offsets><italic><offsets xml_i="34141" xml_f="34142" txt_i="14616" txt_f="14617">P</offsets></italic><offsets xml_i="34151" xml_f="34374" txt_i="14617" txt_f="14840">=0.083). On the other hand, 391 (44.0%) patients had a HASBLED score of ≥3. There was no difference in the proportion of patients with HASBLED score of ≥3 between the alert (208; 45.7%) and the control (183; 42.2%) groups (</offsets><italic><offsets xml_i="34382" xml_f="34383" txt_i="14840" txt_f="14841">P</offsets></italic><offsets xml_i="34392" xml_f="34615" txt_i="14841" txt_f="15064">=0.287). There were only 32 (3.6%) patients with a HASBLED score ≥5 (Table S2). There was no difference in the proportion of patients with HASBLED score of ≥5 between the alert (16; 3.5%) and the control (16; 3.7%) groups (</offsets><italic><offsets xml_i="34623" xml_f="34624" txt_i="15064" txt_f="15065">P</offsets></italic><offsets xml_i="34633" xml_f="34641" txt_i="15065" txt_f="15073">=0.892).</offsets></p></sec><sec id="jah31637-sec-0013"><title><offsets xml_i="34686" xml_f="34696" txt_i="15075" txt_f="15085">End Points</offsets></title><p><offsets xml_i="34707" xml_f="34843" txt_i="15086" txt_f="15222">Overall, 100 (22.0%) patients from the alert group versus 69 (15.9%) from the control group received an adequate OAC prescription (Table</offsets><italic><offsets xml_i="34851" xml_f="34852" txt_i="15222" txt_f="15223"> </offsets></italic><offsets xml_i="34861" xml_f="34862" txt_i="15223" txt_f="15224">
</offsets><xref rid="jah31637-tbl-0003" ref-type="table-wrap"><offsets xml_i="34914" xml_f="34915" txt_i="15224" txt_f="15225">3</offsets></xref><offsets xml_i="34922" xml_f="34945" txt_i="15225" txt_f="15248">) (relative risk 1.38; </offsets><italic><offsets xml_i="34953" xml_f="34954" txt_i="15248" txt_f="15249">P</offsets></italic><offsets xml_i="34963" xml_f="35176" txt_i="15249" txt_f="15462">=0.021). In patients who did not receive an adequate OAC prescription at discharge, aspirin 100 mg per day was ordered in 199 (56.1%) patients from the alert group and 183 (50.3%) patients from the control group (</offsets><italic><offsets xml_i="35184" xml_f="35185" txt_i="15462" txt_f="15463">P</offsets></italic><offsets xml_i="35194" xml_f="35306" txt_i="15463" txt_f="15575">=0.12); an adenosine diphosphate‐receptor antagonist was ordered in 81 (22.8%) versus 81 (22.3%), respectively (</offsets><italic><offsets xml_i="35314" xml_f="35315" txt_i="15575" txt_f="15576">P</offsets></italic><offsets xml_i="35324" xml_f="35414" txt_i="15576" txt_f="15666">=0.86); dual antiplatelet therapy was ordered in 55 (15.5%) and 63 (17.3%), respectively (</offsets><italic><offsets xml_i="35422" xml_f="35423" txt_i="15666" txt_f="15667">P</offsets></italic><offsets xml_i="35432" xml_f="35571" txt_i="15667" txt_f="15806">=0.51). OAC or antiplatelet therapy was prescribed in 325 (71.4%) patients from the alert group versus 271 (62.4%) from the control group (</offsets><italic><offsets xml_i="35579" xml_f="35580" txt_i="15806" txt_f="15807">P</offsets></italic><offsets xml_i="35589" xml_f="35597" txt_i="15807" txt_f="15815">=0.004).</offsets></p><table-wrap id="jah31637-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label><offsets xml_i="35697" xml_f="35704" txt_i="15816" txt_f="15823">Table 3</offsets></label><caption><p><offsets xml_i="35724" xml_f="35817" txt_i="15823" txt_f="15916">Vitamin K Antagonist and Direct Oral Anticoagulant Therapy Stratified for Randomization Group</offsets></p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"></col><col style="border-right:solid 1px #000000" span="1"></col><col style="border-right:solid 1px #000000" span="1"></col><col style="border-right:solid 1px #000000" span="1"></col><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"></th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1"><offsets xml_i="36321" xml_f="36326" txt_i="15917" txt_f="15922">Group</offsets></th><th align="left" rowspan="2" valign="top" colspan="1"><offsets xml_i="36385" xml_f="36386" txt_i="15922" txt_f="15923">
</offsets><italic><offsets xml_i="36394" xml_f="36395" txt_i="15923" txt_f="15924">P</offsets></italic><offsets xml_i="36404" xml_f="36410" txt_i="15924" txt_f="15930"> Value</offsets><xref ref-type="fn" rid="jah31637-note-0012"><offsets xml_i="36455" xml_f="36456" txt_i="15930" txt_f="15931">a</offsets></xref><offsets xml_i="36463" xml_f="36464" txt_i="15931" txt_f="15932">
</offsets></th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="36572" xml_f="36579" txt_i="15932" txt_f="15939">Control</offsets></th><th align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="36638" xml_f="36643" txt_i="15939" txt_f="15944">Alert</offsets></th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1"><offsets xml_i="36713" xml_f="36729" txt_i="15944" txt_f="15960">Any prescription</offsets></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><offsets xml_i="36809" xml_f="36829" txt_i="15961" txt_f="15981">Vitamin K antagonist</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="36875" xml_f="36883" txt_i="15982" txt_f="15990">32 (7.4)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="36929" xml_f="36938" txt_i="15991" txt_f="16000">52 (11.4)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="36984" xml_f="36989" txt_i="16001" txt_f="16006">0.039</offsets></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><offsets xml_i="37069" xml_f="37094" txt_i="16007" txt_f="16032">Direct oral anticoagulant</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="37140" xml_f="37148" txt_i="16033" txt_f="16041">38 (8.8)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="37194" xml_f="37203" txt_i="16042" txt_f="16051">48 (10.5)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="37249" xml_f="37254" txt_i="16052" txt_f="16057">0.366</offsets></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><offsets xml_i="37334" xml_f="37339" txt_i="16058" txt_f="16063">Total</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="37385" xml_f="37394" txt_i="16064" txt_f="16073">70 (16.1)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="37440" xml_f="37450" txt_i="16074" txt_f="16084">100 (22.0)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="37496" xml_f="37501" txt_i="16085" txt_f="16090">0.027</offsets></td></tr><tr><td align="left" colspan="4" rowspan="1"><offsets xml_i="37556" xml_f="37577" txt_i="16091" txt_f="16112">Adequate prescription</offsets></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><offsets xml_i="37657" xml_f="37677" txt_i="16113" txt_f="16133">Vitamin K antagonist</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="37723" xml_f="37731" txt_i="16134" txt_f="16142">32 (7.4)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="37777" xml_f="37786" txt_i="16143" txt_f="16152">52 (11.4)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="37832" xml_f="37837" txt_i="16153" txt_f="16158">0.039</offsets></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><offsets xml_i="37917" xml_f="37942" txt_i="16159" txt_f="16184">Direct oral anticoagulant</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="37988" xml_f="37996" txt_i="16185" txt_f="16193">37 (8.5)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="38042" xml_f="38051" txt_i="16194" txt_f="16203">48 (10.5)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="38097" xml_f="38102" txt_i="16204" txt_f="16209">0.305</offsets></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><offsets xml_i="38182" xml_f="38187" txt_i="16210" txt_f="16215">Total</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="38233" xml_f="38242" txt_i="16216" txt_f="16225">69 (15.9)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="38288" xml_f="38298" txt_i="16226" txt_f="16236">100 (22.0)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="38344" xml_f="38349" txt_i="16237" txt_f="16242">0.021</offsets></td></tr></tbody></table><table-wrap-foot><fn id="jah31637-note-0011"><p><offsets xml_i="38423" xml_f="38458" txt_i="16243" txt_f="16278">Values are numbers and percentages.</offsets></p></fn><fn id="jah31637-note-0012"><label><offsets xml_i="38502" xml_f="38503" txt_i="16279" txt_f="16280">a</offsets></label><p><offsets xml_i="38514" xml_f="38531" txt_i="16280" txt_f="16297">Calculated with χ</offsets><sup><offsets xml_i="38536" xml_f="38537" txt_i="16297" txt_f="16298">2</offsets></sup><offsets xml_i="38543" xml_f="38549" txt_i="16298" txt_f="16304"> test.</offsets></p></fn></table-wrap-foot></table-wrap><p><offsets xml_i="38592" xml_f="38701" txt_i="16305" txt_f="16414">In 48 (10.5%) patients from the alert group, physicians used the electronic entry system to calculate the CHA</offsets><sub><offsets xml_i="38706" xml_f="38707" txt_i="16414" txt_f="16415">2</offsets></sub><offsets xml_i="38713" xml_f="38715" txt_i="16415" txt_f="16417">DS</offsets><sub><offsets xml_i="38720" xml_f="38721" txt_i="16417" txt_f="16418">2</offsets></sub><offsets xml_i="38727" xml_f="39178" txt_i="16418" txt_f="16869">‐VASc score. Among these, 19 (39.6%) calculations were identical as compared with data obtained from discharge letters and 16 (37.5%) calculations differed by 1 point. Only 1 patient judged to have an increased score according to information from the discharge letter was classified as a low‐risk patient by the physician in charge. In patients from the alert group, an OAC prescription was present in 11 (22.9%) patients whose physicians used the CHA</offsets><sub><offsets xml_i="39183" xml_f="39184" txt_i="16869" txt_f="16870">2</offsets></sub><offsets xml_i="39190" xml_f="39192" txt_i="16870" txt_f="16872">DS</offsets><sub><offsets xml_i="39197" xml_f="39198" txt_i="16872" txt_f="16873">2</offsets></sub><offsets xml_i="39204" xml_f="39290" txt_i="16873" txt_f="16959">‐VASc score calculation tool and 89 (21.9%) patients whose physicians did not use it (</offsets><italic><offsets xml_i="39298" xml_f="39299" txt_i="16959" txt_f="16960">P</offsets></italic><offsets xml_i="39308" xml_f="39315" txt_i="16960" txt_f="16967">=0.87).</offsets></p></sec></sec><sec id="jah31637-sec-0014"><title><offsets xml_i="39366" xml_f="39376" txt_i="16970" txt_f="16980">Discussion</offsets></title><p><offsets xml_i="39387" xml_f="39597" txt_i="16981" txt_f="17191">In this randomized controlled clinical trial, the computer‐based alert system increased adequate OAC prescription rates as compared to standard of care among consecutive hospitalized OAC‐naïve patients with AF.</offsets></p><p><offsets xml_i="39604" xml_f="39792" txt_i="17192" txt_f="17380">The finding is in agreement with the results of a previous study from our group testing the effectiveness of a clinical decision support system in the prevention of venous thromboembolism.</offsets><xref rid="jah31637-bib-0016" ref-type="ref"><offsets xml_i="39837" xml_f="39839" txt_i="17380" txt_f="17382">16</offsets></xref><offsets xml_i="39846" xml_f="40301" txt_i="17382" txt_f="17837"> Taken the findings from these 2 randomized trials together, there is increasing evidence supporting the implementation of computerized decision support systems in cardiovascular medicine. Both alert systems significantly increased adequate prescription rates. In the present study, the observed rates of adequate OAC prescription of 22.0% in the alert group and 15.9% in the control group were somewhat lower than expected (30% versus 20%), respectively.</offsets></p><p><offsets xml_i="40308" xml_f="40346" txt_i="17838" txt_f="17876">Of note, the tool to calculate the CHA</offsets><sub><offsets xml_i="40351" xml_f="40352" txt_i="17876" txt_f="17877">2</offsets></sub><offsets xml_i="40358" xml_f="40360" txt_i="17877" txt_f="17879">DS</offsets><sub><offsets xml_i="40365" xml_f="40366" txt_i="17879" txt_f="17880">2</offsets></sub><offsets xml_i="40372" xml_f="40569" txt_i="17880" txt_f="18077">‐VASc score was used in a minority of patients. Nevertheless, a simple reminder of untreated AF has obviously increased awareness and improved treatment quality offered by the physicians in charge.</offsets></p><p><offsets xml_i="40576" xml_f="40606" txt_i="18078" txt_f="18108">Due to the poor use of the CHA</offsets><sub><offsets xml_i="40611" xml_f="40612" txt_i="18108" txt_f="18109">2</offsets></sub><offsets xml_i="40618" xml_f="40620" txt_i="18109" txt_f="18111">DS</offsets><sub><offsets xml_i="40625" xml_f="40626" txt_i="18111" txt_f="18112">2</offsets></sub><offsets xml_i="40632" xml_f="40703" txt_i="18112" txt_f="18183">‐VASc score tool, we were only able to evaluate the accuracy of the CHA</offsets><sub><offsets xml_i="40708" xml_f="40709" txt_i="18183" txt_f="18184">2</offsets></sub><offsets xml_i="40715" xml_f="40717" txt_i="18184" txt_f="18186">DS</offsets><sub><offsets xml_i="40722" xml_f="40723" txt_i="18186" txt_f="18187">2</offsets></sub><offsets xml_i="40729" xml_f="40848" txt_i="18187" txt_f="18306">‐VASc score calculation in about 10% of the patients from the alert group. As compared with our calculations of the CHA</offsets><sub><offsets xml_i="40853" xml_f="40854" txt_i="18306" txt_f="18307">2</offsets></sub><offsets xml_i="40860" xml_f="40862" txt_i="18307" txt_f="18309">DS</offsets><sub><offsets xml_i="40867" xml_f="40868" txt_i="18309" txt_f="18310">2</offsets></sub><offsets xml_i="40874" xml_f="40938" txt_i="18310" txt_f="18374">‐VASc score based on information from discharge letters, the CHA</offsets><sub><offsets xml_i="40943" xml_f="40944" txt_i="18374" txt_f="18375">2</offsets></sub><offsets xml_i="40950" xml_f="40952" txt_i="18375" txt_f="18377">DS</offsets><sub><offsets xml_i="40957" xml_f="40958" txt_i="18377" txt_f="18378">2</offsets></sub><offsets xml_i="40964" xml_f="41169" txt_i="18378" txt_f="18583">‐VASc scores calculated with the tool were quite accurate. Only 1 patient was classified as low risk by the tool but as high risk by information from the discharge letter. Interestingly, the use of the CHA</offsets><sub><offsets xml_i="41174" xml_f="41175" txt_i="18583" txt_f="18584">2</offsets></sub><offsets xml_i="41181" xml_f="41183" txt_i="18584" txt_f="18586">DS</offsets><sub><offsets xml_i="41188" xml_f="41189" txt_i="18586" txt_f="18587">2</offsets></sub><offsets xml_i="41195" xml_f="41297" txt_i="18587" txt_f="18689">‐VASc score calculation tool had no impact on the OAC prescription rate. Reasons for not using the CHA</offsets><sub><offsets xml_i="41302" xml_f="41303" txt_i="18689" txt_f="18690">2</offsets></sub><offsets xml_i="41309" xml_f="41311" txt_i="18690" txt_f="18692">DS</offsets><sub><offsets xml_i="41316" xml_f="41317" txt_i="18692" txt_f="18693">2</offsets></sub><offsets xml_i="41323" xml_f="41372" txt_i="18693" txt_f="18742">‐VASc score tool may include knowledge of the CHA</offsets><sub><offsets xml_i="41377" xml_f="41378" txt_i="18742" txt_f="18743">2</offsets></sub><offsets xml_i="41384" xml_f="41386" txt_i="18743" txt_f="18745">DS</offsets><sub><offsets xml_i="41391" xml_f="41392" txt_i="18745" txt_f="18746">2</offsets></sub><offsets xml_i="41398" xml_f="41688" txt_i="18746" txt_f="19036">‐VASc score prior to the alert, time constraints, the high rate of non‐sense alerts, and known contraindication to OAC because of an increased risk of bleeding. In this respect it was notable that ≈40% of the patients in the study had a HASBLED score ≥3, indicating increased bleeding risk.</offsets><xref rid="jah31637-bib-0011" ref-type="ref"><offsets xml_i="41733" xml_f="41735" txt_i="19036" txt_f="19038">11</offsets></xref><offsets xml_i="41742" xml_f="42157" txt_i="19038" txt_f="19453"> This may also be a reason for the overall low OAC prescription rate in the study. Of relevance, a considerable amount of patients received antiplatelet therapy, and as compared with the control group more patients from the alert group received OAC or antiplatelet therapy. A previous clinical decision support system was developed to facilitate clinical decision making with regard to OAC treatment in AF patients.</offsets><xref rid="jah31637-bib-0018" ref-type="ref"><offsets xml_i="42202" xml_f="42204" txt_i="19453" txt_f="19455">18</offsets></xref><offsets xml_i="42211" xml_f="42264" txt_i="19455" txt_f="19508"> This system included both the calculation of the CHA</offsets><sub><offsets xml_i="42269" xml_f="42270" txt_i="19508" txt_f="19509">2</offsets></sub><offsets xml_i="42276" xml_f="42278" txt_i="19509" txt_f="19511">DS</offsets><sub><offsets xml_i="42283" xml_f="42284" txt_i="19511" txt_f="19512">2</offsets></sub><offsets xml_i="42290" xml_f="42503" txt_i="19512" txt_f="19725">‐VASc and the HASBLED scores. However, it did not include what we think is the main benefit of our electronic alert system, namely, to issue alerts to patients with suspected AF without an active OAC prescription.</offsets></p><p><offsets xml_i="42510" xml_f="43602" txt_i="19726" txt_f="20818">A limitation of our alert system was the high rate of non‐sense alerts for patients who were not OAC‐naïve because alerts were often issued before anticoagulation treatment was ordered through the electronic prescription system. Prior to the randomization phase, the rate of non‐sense alerts was reduced by issuing alerts not directly on admission but 24 hours after the onset of the hospital stay. Very few departments at the Inselspital did use the electronic patient chart only for entering diagnoses but not for prescription of pharmaceutical treatments. This problem was then solved through sending alerts only if at least 1 drug has been prescribed through the alert system at 24 hours. Another problem was that many patients had paused OAC therapy due to planned surgical procedures. Patients with paused OAC therapy were identified by reviewing medical discharge letters and then excluded from the analysis. In addition, alerts were issued for several patients in whom AF was identified by the alert system but not confirmed by the treating physician. We think that the use of the CHA</offsets><sub><offsets xml_i="43607" xml_f="43608" txt_i="20818" txt_f="20819">2</offsets></sub><offsets xml_i="43614" xml_f="43616" txt_i="20819" txt_f="20821">DS</offsets><sub><offsets xml_i="43621" xml_f="43622" txt_i="20821" txt_f="20822">2</offsets></sub><offsets xml_i="43628" xml_f="44749" txt_i="20822" txt_f="21943">‐VASc score calculation tool and the rate of adequate OAC prescription can be further improved by reducing the rate of non‐sense alerts. We plan to continuously improve the identification of OAC‐naïve patients and integrate the alert system in routine clinical practice. Further limitations of our study were the single‐center setting, and the lack of systematic evaluation of why anticoagulation was not given. Physicians' acceptance of the alert was not assessed systematically either, nor was the potential impact of other electronic alert systems on the present alert system considered. The strengths of the present study include its randomized design and chart reviews of bleeding and stroke risks. The intervention was designed to modify physician behavior, but randomization was at the patient level. Since individual physicians may have treated several patients, the observations are not independent, and the outcome analysis typically should account for clustering of patients within physicians. However, since more than 500 physicians were involved in the study, such a cluster analysis was deemed less helpful.</offsets></p><p><offsets xml_i="44756" xml_f="45331" txt_i="21944" txt_f="22519">An increase in the prescription rate of anticoagulant treatment in AF may translate into a reduction of the future risk of stroke. We did not collect data to investigate the effect of the alert system on the risk of stroke and systemic embolism. A prospective multicenter trial testing the effects of the alert system on end points is therefore encouraged. The total cost for the entire project was US $230 000, of which the majority was used for developing and testing of the alert system. Therefore, the implementation of the alert system in other hospitals seems feasible.</offsets></p><p><offsets xml_i="45338" xml_f="45818" txt_i="22520" txt_f="23000">In conclusion, we developed and tested a novel electronic decision support system for improving adequate stroke prevention measures among hospitalized OAC‐naïve patients with AF. In comparison to routine clinical practice, this alert system modestly increased adequate OAC prescription. Our results suggest that hospitals with electronic patient chart and order entry systems may consider implementing similar computer‐based alerts to increase physician awareness of untreated AF.</offsets></p></sec><sec id="jah31637-sec-0016"><title><offsets xml_i="45863" xml_f="45881" txt_i="23002" txt_f="23020">Sources of Funding</offsets></title><p><offsets xml_i="45892" xml_f="46057" txt_i="23021" txt_f="23186">The project was supported by an unrestricted grant from Bayer Healthcare AG (Leverkusen, Germany) and by a grant from the Inselspital Foundation (Bern, Switzerland).</offsets></p></sec><sec id="jah31637-sec-0017"><title><offsets xml_i="46102" xml_f="46113" txt_i="23188" txt_f="23199">Disclosures</offsets></title><p><offsets xml_i="46124" xml_f="46390" txt_i="23200" txt_f="23466">Silbernagel received minor honoraria, travel funding, and a research grant from Amgen Inc., Thousand Oaks, CA. Kucher received speaker honoraria from Bayer Healthcare AG, Leverkusen, Germany. Spirk is an employee of Sanofi‐Aventis (Suisse) SA (Vernier, Switzerland).</offsets></p></sec><sec sec-type="supplementary-material"><title><offsets xml_i="46446" xml_f="46468" txt_i="23468" txt_f="23490">Supporting information</offsets></title><supplementary-material content-type="local-data" id="jah31637-sup-0001"><caption><p><offsets xml_i="46561" xml_f="46562" txt_i="23491" txt_f="23492">
</offsets><bold><offsets xml_i="46568" xml_f="46577" txt_i="23492" txt_f="23501">Table S1.</offsets></bold><offsets xml_i="46584" xml_f="46610" txt_i="23501" txt_f="23527"> The Categories of the CHA</offsets><sub><offsets xml_i="46615" xml_f="46616" txt_i="23527" txt_f="23528">2</offsets></sub><offsets xml_i="46622" xml_f="46624" txt_i="23528" txt_f="23530">DS</offsets><sub><offsets xml_i="46629" xml_f="46630" txt_i="23530" txt_f="23531">2</offsets></sub><offsets xml_i="46636" xml_f="46682" txt_i="23531" txt_f="23577">‐VASc Score Stratified for Randomization Group</offsets></p><p><offsets xml_i="46689" xml_f="46690" txt_i="23578" txt_f="23579">
</offsets><bold><offsets xml_i="46696" xml_f="46705" txt_i="23579" txt_f="23588">Table S2.</offsets></bold><offsets xml_i="46712" xml_f="46783" txt_i="23588" txt_f="23659"> The Categories of the HASBLED Score Stratified for Randomization Group</offsets></p><p><offsets xml_i="46790" xml_f="46791" txt_i="23660" txt_f="23661">
</offsets><bold><offsets xml_i="46797" xml_f="46807" txt_i="23661" txt_f="23671">Figure S1.</offsets></bold><offsets xml_i="46814" xml_f="46818" txt_i="23671" txt_f="23675"> CHA</offsets><sub><offsets xml_i="46823" xml_f="46824" txt_i="23675" txt_f="23676">2</offsets></sub><offsets xml_i="46830" xml_f="46832" txt_i="23676" txt_f="23678">DS</offsets><sub><offsets xml_i="46837" xml_f="46838" txt_i="23678" txt_f="23679">2</offsets></sub><offsets xml_i="46844" xml_f="46984" txt_i="23679" txt_f="23819">‐VASc score calculation tool for physicians in charge of patients with atrial fibrillation but without ongoing oral anticoagulant treatment.</offsets></p></caption><media xlink:href="JAH3-5-e003776-s001.pdf"><caption><p><offsets xml_i="47054" xml_f="47090" txt_i="23820" txt_f="23856">Click here for additional data file.</offsets></p></caption></media></supplementary-material></sec></body><back><ack id="jah31637-sec-0015"><title>Acknowledgments</title><p>The authors thank Stefanie Reusser and Diego Lopez for their technical assistance.</p></ack><ref-list content-type="cited-references" id="jah31637-bibl-0001"><title>References</title><ref id="jah31637-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah31637-cit-0001">
<string-name>
<surname>Schnabel</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Yin</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Gona</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Larson</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Beiser</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>McManus</surname>
<given-names>DD</given-names>
</string-name>, <string-name>
<surname>Newton‐Cheh</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lubitz</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Magnani</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Ellinor</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Seshadri</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wolf</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Vasan</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Benjamin</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Levy</surname>
<given-names>D</given-names>
</string-name>. <article-title>50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study</article-title>. <source>Lancet</source>. <year>2015</year>;<volume>386</volume>:<fpage>154</fpage>–<lpage>162</lpage>.<pub-id pub-id-type="pmid">25960110</pub-id></mixed-citation></ref><ref id="jah31637-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah31637-cit-0002">
<string-name>
<surname>Chugh</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Havmoeller</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Narayanan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Rienstra</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Benjamin</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Gillum</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>YH</given-names>
</string-name>, <string-name>
<surname>McAnulty</surname>
<given-names>JH</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>ZJ</given-names>
</string-name>, <string-name>
<surname>Forouzanfar</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Naghavi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mensah</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Ezzati</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Murray</surname>
<given-names>CJ</given-names>
</string-name>. <article-title>Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study</article-title>. <source>Circulation</source>. <year>2014</year>;<volume>129</volume>:<fpage>837</fpage>–<lpage>847</lpage>.<pub-id pub-id-type="pmid">24345399</pub-id></mixed-citation></ref><ref id="jah31637-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah31637-cit-0003">
<string-name>
<surname>Steger</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Pratter</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Martinek‐Bregel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Avanzini</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Valentin</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Slany</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Stöllberger</surname>
<given-names>C</given-names>
</string-name>. <article-title>Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry</article-title>. <source>Eur Heart J</source>. <year>2004</year>;<volume>25</volume>:<fpage>1734</fpage>–<lpage>1740</lpage>.<pub-id pub-id-type="pmid">15451152</pub-id></mixed-citation></ref><ref id="jah31637-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah31637-cit-0004">
<string-name>
<surname>Kirchhof</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Auricchio</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bax</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Crijns</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Camm</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Diener</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Goette</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hindricks</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Hohnloser</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kappenberger</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Kuck</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>Lip</surname>
<given-names>GY</given-names>
</string-name>, <string-name>
<surname>Olsson</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Meinertz</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Priori</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ravens</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Steinbeck</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Svernhage</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Tijssen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Vincent</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Breithardt</surname>
<given-names>G</given-names>
</string-name>. <article-title>Outcome parameters for trials in atrial fibrillation: executive summary</article-title>. <source>Eur Heart J</source>. <year>2007</year>;<volume>28</volume>:<fpage>2803</fpage>–<lpage>2817</lpage>.<pub-id pub-id-type="pmid">17897924</pub-id></mixed-citation></ref><ref id="jah31637-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah31637-cit-0005">
<string-name>
<surname>Goto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bhatt</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Rother</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Alberts</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hill</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Ikeda</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Uchiyama</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>D'Agostino</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ohman</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Liau</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Hirsch</surname>
<given-names>AT</given-names>
</string-name>, <string-name>
<surname>Mas</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Corbalán</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Aichner</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Steg</surname>
<given-names>PG</given-names>
</string-name>; <collab collab-type="authors">REACH Registry Investigators</collab>
. <article-title>Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis</article-title>. <source>Am Heart J</source>. <year>2008</year>;<volume>156</volume>:<fpage>855</fpage>–<lpage>863</lpage>.<pub-id pub-id-type="pmid">19061698</pub-id></mixed-citation></ref><ref id="jah31637-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah31637-cit-0006">
<string-name>
<surname>January</surname>
<given-names>CT</given-names>
</string-name>, <string-name>
<surname>Wann</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Alpert</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Calkins</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Cigarroa</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Cleveland</surname>
<given-names>JC</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Conti</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Ellinor</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Ezekowitz</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Field</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Murray</surname>
<given-names>KT</given-names>
</string-name>, <string-name>
<surname>Sacco</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Stevenson</surname>
<given-names>WG</given-names>
</string-name>, <string-name>
<surname>Tchou</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Tracy</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Yancy</surname>
<given-names>CW</given-names>
</string-name>; <collab collab-type="authors">ACC/AHA Task Force Members</collab>
. <article-title>2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society</article-title>. <source>Circulation</source>. <year>2014</year>;<volume>130</volume>:<fpage>2071</fpage>–<lpage>2104</lpage>.<pub-id pub-id-type="pmid">24682348</pub-id></mixed-citation></ref><ref id="jah31637-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah31637-cit-0007">
<string-name>
<surname>Connolly</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Ezekowitz</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Yusuf</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Eikelboom</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Oldgren</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Parekh</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pogue</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Reilly</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Themeles</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Varrone</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Alings</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Xavier</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Diaz</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Darius</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Diener</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Joyner</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Wallentin</surname>
<given-names>L</given-names>
</string-name>; <collab collab-type="authors">RE‐LY Steering Committee and Investigators</collab>
. <article-title>Dabigatran versus warfarin in patients with atrial fibrillation</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>361</volume>:<fpage>1139</fpage>–<lpage>1151</lpage>.<pub-id pub-id-type="pmid">19717844</pub-id></mixed-citation></ref><ref id="jah31637-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah31637-cit-0008">
<string-name>
<surname>Connolly</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Ezekowitz</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Yusuf</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Reilly</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Wallentin</surname>
<given-names>L</given-names>
</string-name>. <article-title>Newly identified events in the RE‐LY trial</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>:<fpage>1875</fpage>–<lpage>1876</lpage>.<pub-id pub-id-type="pmid">21047252</pub-id></mixed-citation></ref><ref id="jah31637-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah31637-cit-0009">
<string-name>
<surname>Granger</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Alexander</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>McMurray</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Lopes</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Hylek</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Hanna</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Al‐Khalidi</surname>
<given-names>HR</given-names>
</string-name>, <string-name>
<surname>Ansell</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Atar</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Avezum</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bahit</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Diaz</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Easton</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Ezekowitz</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Flaker</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Garcia</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Geraldes</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gersh</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Golitsyn</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Goto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hermosillo</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Hohnloser</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Horowitz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mohan</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Jansky</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Lopez‐Sendon</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Pais</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Parkhomenko</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Verheugt</surname>
<given-names>FW</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wallentin</surname>
<given-names>L</given-names>
</string-name>; <collab collab-type="authors">ARISTOTLE Committees and Investigators</collab>
. <article-title>Apixaban versus warfarin in patients with atrial fibrillation</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>365</volume>:<fpage>981</fpage>–<lpage>992</lpage>.<pub-id pub-id-type="pmid">21870978</pub-id></mixed-citation></ref><ref id="jah31637-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah31637-cit-0010">
<string-name>
<surname>Patel</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Mahaffey</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>Garg</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pan</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Singer</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Hacke</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Breithardt</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Halperin</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Hankey</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Piccini</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Becker</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Nessel</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Paolini</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Berkowitz</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Fox</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Califf</surname>
<given-names>RM</given-names>
</string-name>; <collab collab-type="authors">ROCKET AF Investigators</collab>
. <article-title>Rivaroxaban versus warfarin in nonvalvular atrial fibrillation</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>365</volume>:<fpage>883</fpage>–<lpage>891</lpage>.<pub-id pub-id-type="pmid">21830957</pub-id></mixed-citation></ref><ref id="jah31637-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah31637-cit-0011">
<string-name>
<surname>Camm</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Lip</surname>
<given-names>GY</given-names>
</string-name>, <string-name>
<surname>De Caterina</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Savelieva</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Atar</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hohnloser</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Hindricks</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kirchhof</surname>
<given-names>P</given-names>
</string-name>; <collab collab-type="authors">ESC Committee for Practice Guidelines (CPG)</collab>
. <article-title>2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association</article-title>. <source>Eur Heart J</source>. <year>2012</year>;<volume>33</volume>:<fpage>2719</fpage>–<lpage>2747</lpage>.<pub-id pub-id-type="pmid">22922413</pub-id></mixed-citation></ref><ref id="jah31637-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah31637-cit-0012">
<string-name>
<surname>Kakkar</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Mueller</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Bassand</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Fitzmaurice</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Goldhaber</surname>
<given-names>SZ</given-names>
</string-name>, <string-name>
<surname>Goto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Haas</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hacke</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Lip</surname>
<given-names>GY</given-names>
</string-name>, <string-name>
<surname>Mantovani</surname>
<given-names>LG</given-names>
</string-name>, <string-name>
<surname>Verheugt</surname>
<given-names>FW</given-names>
</string-name>, <string-name>
<surname>Jamal</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Misselwitz</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Rushton‐Smith</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Turpie</surname>
<given-names>AG</given-names>
</string-name>. <article-title>Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>:<fpage>e63479</fpage>.<pub-id pub-id-type="pmid">23704912</pub-id></mixed-citation></ref><ref id="jah31637-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah31637-cit-0013">
<string-name>
<surname>Fuster</surname>
<given-names>V</given-names>
</string-name>. <article-title>A first dilemma in cardiovascular medicine: adherence versus personalized therapy</article-title>. <source>J Am Coll Cardiol</source>. <year>2014</year>;<volume>64</volume>:<fpage>1059</fpage>–<lpage>1060</lpage>.<pub-id pub-id-type="pmid">25190242</pub-id></mixed-citation></ref><ref id="jah31637-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah31637-cit-0014">
<string-name>
<surname>Dexter</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Perkins</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Overhage</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Maharry</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kohler</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>McDonald</surname>
<given-names>CJ</given-names>
</string-name>. <article-title>A computerized reminder system to increase the use of preventive care for hospitalized patients</article-title>. <source>N Engl J Med</source>. <year>2001</year>;<volume>345</volume>:<fpage>965</fpage>–<lpage>970</lpage>.<pub-id pub-id-type="pmid">11575289</pub-id></mixed-citation></ref><ref id="jah31637-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah31637-cit-0015">
<string-name>
<surname>Durieux</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Nizard</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ravaud</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mounier</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Lepage</surname>
<given-names>E</given-names>
</string-name>. <article-title>A clinical decision support system for prevention of venous thromboembolism: effect on physician behavior</article-title>. <source>JAMA</source>. <year>2000</year>;<volume>283</volume>:<fpage>2816</fpage>–<lpage>2821</lpage>.<pub-id pub-id-type="pmid">10838650</pub-id></mixed-citation></ref><ref id="jah31637-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah31637-cit-0016">
<string-name>
<surname>Kucher</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Koo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Quiroz</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cooper</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Paterno</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Soukonnikov</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Goldhaber</surname>
<given-names>SZ</given-names>
</string-name>. <article-title>Electronic alerts to prevent venous thromboembolism among hospitalized patients</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>:<fpage>969</fpage>–<lpage>977</lpage>.<pub-id pub-id-type="pmid">15758007</pub-id></mixed-citation></ref><ref id="jah31637-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah31637-cit-0017">
<string-name>
<surname>Lip</surname>
<given-names>GY</given-names>
</string-name>, <string-name>
<surname>Frison</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Halperin</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Lane</surname>
<given-names>DA</given-names>
</string-name>. <article-title>Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS‐BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score</article-title>. <source>J Am Coll Cardiol</source>. <year>2011</year>;<volume>57</volume>:<fpage>173</fpage>–<lpage>180</lpage>.<pub-id pub-id-type="pmid">21111555</pub-id></mixed-citation></ref><ref id="jah31637-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah31637-cit-0018">
<string-name>
<surname>LaHaye</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Gibbens</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Ball</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Day</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Olesen</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Skanes</surname>
<given-names>AC</given-names>
</string-name>. <article-title>A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation</article-title>. <source>Eur Heart J</source>. <year>2012</year>;<volume>33</volume>:<fpage>2163</fpage>–<lpage>2171</lpage>.<pub-id pub-id-type="pmid">22752615</pub-id></mixed-citation></ref></ref-list></back></article>